Philip E. Johnson, MS, RPh, FASHP

Pharmacy, Oncology, Healthcare, and School Health Consulting
Tampa, FL

Authored Items

Addressing the Value of New Cancer Treatment Options Using the ASCO Model

August 2015, Vol 6, No 7 - VBCC Perspectives

How can cancer care decisions be based on value? Two champions are starting to add science to this controversial discussion, which will eventually help all stakeholders make more informed decisions. Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center has published several articles regarding the high cost of new drugs, claiming that the manufacturers have total price control, which has led to irrational pricing behaviors. Dr Bach promotes a more rational, “value-based” approach, where the outcome determines the price. [ Read More ]